Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New figure in UK international healthcare policy

This article was originally published in Clinica

Executive Summary

The UK's Department of Health (DH) is setting up an International Health Advisory Board to support the chief medical officer in his role as advisor to the government on international health issues. Through a network of experts, the board will be relied upon to provide independent, expert advice; it will also seek to raise the profile of the DH's international health activities. Hamid Ghodse, director of the International Centre of Drug Policy, at the University of London's St George’s college, will be its inaugural chairperson. "Many of today’s health issues need to be considered in an international context and it is essential that the UK plays a full role in the relevant international forums, both learning from the experience of others and making an effective contribution," said Professor Ghodse.

You may also be interested in...



Abbott Inks Automated Insulin Platform Partnership With Insulet

Abbott has signed a partnership with Insulet Corporation to create an integrated technology that automatically adjusts insulin delivery based on personalized glucose data.

EU Fast-Track Loss For Vertex’s CF Triple Combo

Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.

Sawai’s Recent US Launches Outperform Expectations

Sawai’s sales increased on the back of a good performance from recently-launched products in the first nine months of its financial year. However, given the competitive environment the Japanese company is continuing to stick to its full-year forecasts.

Topics

UsernamePublicRestriction

Register

MT044859

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel